| 6613765 |
Use of NK-1 receptor antagonists for treating major depressive disorders |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
2003-09-02 |
$134,242,000 |
| 6271230 |
Use of NK-1 receptor antagonists for treating cognitive disorders |
Jason Matthew Elliott, Neil Roy Curtis, Timothy Harrison, Gregory John Hollingworth, Janusz Jozef Kulagowski +5 more |
2001-08-07 |
$173,294,000 |
| 6114315 |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
2000-09-05 |
$380,270,000 |
| 6100256 |
Use of NK-1 receptors antagonists for treating schizophrenic disorders |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
2000-08-08 |
$326,701,000 |
| 6096729 |
Use of NK-1 receptor antagonists for treating amnestic disorders |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
2000-08-01 |
$169,201,000 |
| 6096766 |
3-benzylaminopiperidines as tachykinin receptor antagonists |
Jason Matthew Elliott, Christopher John Swain |
2000-08-01 |
$169,201,000 |
| 6087348 |
Use of NK-1 receptor antagonists for treating stress disorders |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
2000-07-11 |
$231,145,000 |
| 6071927 |
Spiro-piperidine derivatives and their use as therapeutic agents |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +4 more |
2000-06-06 |
$181,911,000 |
| 6060469 |
Spiro-piperidine derivatives and their use as tachykinin antagonists |
Timothy Harrison, Christopher John Swain, Brian John Williams |
2000-05-09 |
$280,898,000 |
| 5985896 |
Piperidine and morpholine derivatives and their use as therapeutic agents |
Jason Matthew Elliott, Graeme Irvine Stevenson, Christopher John Swain |
1999-11-16 |
$111,398,000 |
| 5981529 |
Substituted indolylpropyl-piperazine derivatives as 5-HT.sub.1D .alpha. agonists |
Mark Stuart Chambers, Sarah Christine Hobbs, Angus Murray MacLeod, Austin John Reeve, Francine Sternfeld +1 more |
1999-11-09 |
$104,304,000 |
| 5977104 |
Use of NK-1 receptor antagonists for treating bipolar disorders |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
1999-11-02 |
$99,873,000 |
| 5952315 |
Use of NK-1 receptor antagonists for treating bipolar disorders |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
1999-09-14 |
$82,986,000 |
| 5929054 |
Use of NK-1 receptor antagonists for treating sexual dysfunctions |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
1999-07-27 |
$152,441,000 |
| 5925627 |
Use of NK-1 receptor antagonists for treating movement disorders |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
1999-07-20 |
$173,701,000 |
| 5919781 |
Use of NK-1 receptor antogonists for treating substance use disorders |
Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson +5 more |
1999-07-06 |
$132,808,000 |
| 5854247 |
Piperazine, piperidine and tetrahydropyridine derivatives useful as 5-HT1 recepter agonists |
Andrew Madin, Victor G. Matassa, Leslie Joseph Street |
1998-12-29 |
$86,110,000 |
| 5854268 |
Azetidine, pyrrolidine and piperidine derivatives |
Sylvie Bourrain, Jose Luis Castro Pineiro, Mark Stuart Chambers, Alexander Richard Guiblin, Sarah Christine Hobbs +9 more |
1998-12-29 |
$86,110,000 |
| 5830892 |
Piperidine and morphonline derivatives and their use as therapeutic agents |
Jason Matthew Elliott, Graeme Irvine Stevenson, Christopher John Swain |
1998-11-03 |
$190,857,000 |
| 5780475 |
Antipsychotic indazole derivatives |
Janusz Jozef Kulagowski, Paul D. Leeson, Adrian L. Smith |
1998-07-14 |
$105,697,000 |
| 5760018 |
Gem-disubstituted azacyclic tachykinin antagonists |
Richard T. Lewis, Angus Murray MacLeod, Graeme Irvine Stevenson |
1998-06-02 |
$86,758,000 |
| 5700809 |
Pyrrolo-pyridine derivatives |
Paul D. Leeson, Adrian L. Smith, Mark Peter Ridgill, Neil Roy Curtis, Janusz Jozef Kulagowski |
1997-12-23 |
$85,162,000 |
| 5686463 |
Oxadiazoles useful in the treatment of senile dementia |
Kevin John Merchant, Angus Murray MacLeod, John Saunders |
1997-11-11 |
$73,728,000 |
| 5665732 |
Indazole derivatives |
Janusz Jozef Kulagowski, Paul D. Leeson, Adrian L. Smith |
1997-09-09 |
$87,414,000 |
| 5665883 |
Aralkoxy and aralkylthio substituted azacyclic compounds as tachykinin antagonists |
Angus Murray MacLeod, Eileen Mary Seward, Christopher John Swain |
1997-09-09 |
$87,414,000 |
